Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates through two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise software that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing programs or systems. The company also provides RxCompanion, a cloud-based MTM software platform designed to aid in the identification and resolution of medication and other health related problems; TruChart, a web-based electronic health record for Programs of All-Inclusive Care for the Elderly (PACE) organizations; PACElogic, which delivers real-time sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state required reporting. In addition, the company offers DoseMeRx, a decision support software; PrescribeWellness, a patient engagement center platform; and clinical pharmacist collaboration, prescription fulfillment and reminder packaging, and pharmacy cost management services, as well as health plan management services, including risk adjustment and third party administrator services. As of December 31, 2020, it served approximately 130 healthcare organizations; and 280 health plans and approximately 14,000 retail pharmacies. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.
IPO Year: 2016
Exchange: NASDAQ
Website: tabularasahealthcare.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2023 | $7.00 → $10.00 | Market Perform → Outperform | SVB Securities |
| 3/2/2022 | $30.00 → $15.00 | Buy | Benchmark |
| 2/28/2022 | $23.00 → $11.00 | Market Perform | SVB Leerink |
| 2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Robert W. Baird |
| 2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Baird |
| 12/2/2021 | $13.00 | Hold | Jefferies |
| 11/8/2021 | $70.00 → $23.00 | Outperform | RBC Capital |
| 11/8/2021 | $40.00 → $23.00 | Market Perform | SVB Leerink |
| 9/24/2021 | $49.00 → $40.00 | Market Perform | SVB Leerink |
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
15-12G - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
SVB Securities upgraded Tabula Rasa HealthCare from Market Perform to Outperform and set a new price target of $10.00 from $7.00 previously
Benchmark reiterated coverage of Tabula Rasa HealthCare with a rating of Buy and set a new price target of $15.00 from $30.00 previously
SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $11.00 from $23.00 previously
Robert W. Baird downgraded Tabula Rasa HealthCare from Outperform to Neutral and set a new price target of $11.00 from $24.00 previously
Baird downgraded Tabula Rasa HealthCare from Outperform to Neutral and set a new price target of $11.00 from $24.00 previously
Jefferies initiated coverage of Tabula Rasa HealthCare with a rating of Hold and set a new price target of $13.00
RBC Capital reiterated coverage of Tabula Rasa HealthCare with a rating of Outperform and set a new price target of $23.00 from $70.00 previously
SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $23.00 from $40.00 previously
SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $40.00 from $49.00 previously
Robert W. Baird initiated coverage of Tabula Rasa HealthCare with a rating of Outperform and set a new price target of $53.00